Use of benzothiopenes to treat and prevent prostate cancer

Details Use of benzothiopenes to treat and prevent prostate cancer Use of benzothiopenes to treat and prevent prostate cancer

2003-07-23

2008-09-16

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07425565

ABSTRACT:
Disclosed herein is a method for treating and preventing prostate cancer, and particularly androgen-independent prostate cancer, the method including administering to a mammal a benzothiopene having the formulaor pharmaceutically acceptable salts or prodrugs thereof, wherein R and R1are each independently selected from the group consisting of hydrogen, —COR2, —COR3, and R4; R2is selected from the group consisting of hydrogen, C1-C14 alkyl, C1-C3 chloroalkyl, C1-C3 fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, and phenyl; R3is phenyl with at least one substitution selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro, trichloromethyl, and trifluoromethyl; R4is selected from the group consisting of C1-C4 alkyl, C5-C7 cycloalkyl, and benzyl; and R5is selected from the group consisting of oxygen and —C═O. The method may further include the administration of an estrogen lowering drug to enhance efficacy of the compound of the present invention.

REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4358593 (1982-11-01), Jones et al.
patent: 4418068 (1983-11-01), Jones
patent: 5135849 (1992-08-01), Soto et al.
patent: 5795909 (1998-08-01), Shashoua et al.
patent: 5821254 (1998-10-01), Sporn et al.
patent: 5889042 (1999-03-01), MacLean et al.
patent: 5945412 (1999-08-01), Fuh et al.
patent: 5962505 (1999-10-01), Bobrove et al.
patent: 6099823 (2000-08-01), Falb
patent: 6121292 (2000-09-01), Chandrasekhar et al.
patent: 6124311 (2000-09-01), Chandrasekhar et al.
patent: 6159696 (2000-12-01), Dijkema et al.
patent: 6204286 (2001-03-01), Cameron et al.
patent: 6225308 (2001-05-01), Miller et al.
patent: 6632447 (2003-10-01), Steiner et al.
patent: 2003/0158164 (2003-08-01), Ohta et al.
patent: 2004/0002484 (2004-01-01), Hanson et al.
patent: 2004/0142973 (2004-07-01), Castle
patent: 0652004 (1994-10-01), None
patent: WO-01/27129 (2001-04-01), None
Raghow et al, Cancer Res 62, 1370-1376, Mar. 1, 2002.
Clinical Trials, www.clinicaltrials.gov/clinicaltrials/PCI-00-105, 1-3, Jul. 1, 2001.
Neubauer et al. Raloxifene (LY156758) Produces Antimetastatic Responses and Extends Survival in the PAIII Rat Prostatic Adenocarcinoma Model. The Prostate, 27:220-229 (1995).
Lau et al. Expression of Estrogen Recpetor (ER)-a and ER-b in Normal and Malignant Prostatic Epithelial Cells: Regulation by Methylation and Involvement in Growth Regulation. Cancer Research, 60:3175-3182 (2000).
Neubauer, B., et al., “Comparative Antitumor Effects of Hormonal Ablation, Estrogen Agonist, Estrogen Cytotoxic Derivative, and Antiestrogen in the PAIII Rat Prostatic Adenocarcinoma”, Cancer Research 52, 4663-4671, 1992.
Neubauer, B. et al., “Raloxifene (LY156758) Produces Antimetastatic Responses and Extends Survival in the PAIII Rat Prostatic Adenocarcinoma Model”, The Prostate 27:220-229 (1995).
Diaz, Michael, et al., “Management of Androgen-Independent Prostate Cancer”,Cancer Control, vol. 11, No. 6 (2004) pp. 364-373.
Kim, Isaac Y., et al., “Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis in Androgen-independent Human Prostate Cancer Cell Lines”,Cancer Research62(18) (Sep. 15, 2002) pp. 5365-5369.
Database HCAPLUS on STN (Columbus, OH, USA) DN 137:363046, Agus, D., “Use of benzothiphenes to treat and prevent prostate cancer”, WO 2002089801 A1, 20021114, abstract.
Database HCAPLUS on STN (Columbus, OH, USA) DN 138:66287, Kim, I. et al, Cancer Research, 2002, (62(13) 3649-3653, abstract.
Database HCAPLUS on STN (Columbus, OH, USA) DN 138:255252, Guzi, T. et al, “Preparation of substituted 1-benzhydryl-4-[2-(4-17-.beta.-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases,” WO 2003022835 A1, 20030320, abstract.

Affiliated with

Also associated with

Rating

Use of benzothiopenes to treat and prevent prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of benzothiopenes to treat and prevent prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of benzothiopenes to treat and prevent prostate cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3981836